Bipolar Hormone Therapy, BAT for Prostate Cancer, BAT Patient Guide
Cancer ABCs
Bipolar Androgen Therapy (BAT): A Patient's ...

This complete guide to Bipolar Androgen Therapy (BAT) should be your stepping-off point if you are interested in using BAT to treat your castrate-resistant prostate cancer (CrPC).

Bipolar Androgen Therapy (BAT): A Patient's Guide
Radiopharmaceutical Treat
Cancer ABCs
Which is Better, 177Lu-PSMA-617 (Pluvicto) or ...

Several men have asked us if they are better off having 177Lu-PSMA-617 (Pluvicto) or Xofigo, a radiopharmaceutical drug that treats bone metastases. There is no simple answer, and the answer is not the same for each of us. Making a sound decision can be helped by understanding the mode of action and the limits of each treatment.

Which is Better, 177Lu-PSMA-617 (Pluvicto) or Xofigo (Radium-223)
PARP Inhibitors, Companion Diagnostics, BRACA
Cancer ABCs
Understanding the PARP Inhibitors - Who Will ...

LYNPARZA (olaparib) and RUBRACA (rucaparib) are PARP Inhibitors that were FDA approved in May of 2020 for men with castrate resistant prostate cancer who also have certain genetic mutations. The FDA also approved certain Companion Diagnostic genetic tests to go along with the decision making to use these PARP Inhibitors.

There is a lot of information now available with these recent developments which makes decision making confusing.

Understanding the PARP Inhibitors - Who Will Benefit?
Radiation Side Effect Man, Managing Radiation Side
Cancer ABCs
Managing Late Stage Radiation Side Effects

There are several possible side effects that can result from receiving radiation treatment. The most common of these side effects include the development of scar tissue that makes it hard to urinate (pee), defecate (poop), and in some instances, link the activity of either peeing and pooping together; bladder or colon bleeding and diarrhea. 

Managing Late Stage Radiation Side Effects

Jevtana

, ,

177Lu-PSMA-617 Theranostics Might Be More Active and Safer than Cabazitaxel 

, ,
177Lu-PSMA-617 Theranostics Might Be More Active and Safer than Cabazitaxel 

The trial showed that the LuPSMA treatment delayed prostate cancer progression versus Jevtana, with a comparable benefit observed in radiographic progression-free survival and PSA progression-free survival.

, ,

Optimal Chemo-Hormonal Sequencing for mCRPC Maybe Taxotere – Zytiga – Jevtana – Xtandi 

, ,
Optimal Chemo-Hormonal Sequencing for mCRPC Maybe Taxotere – Zytiga – Jevtana – Xtandi 

Optimal Chemo-Hormonal Sequencing for metastatic castrate resistant prostate cancer (mCRPC) maybe Taxotere – Zytiga – Jevtana – Xtandi

,

Docetaxel (Taxotere) vs. Jevtana (Cabazitaxel)

,
Docetaxel (Taxotere) vs. Jevtana (Cabazitaxel)

The study concluded that significantly more men preferred Jevtana compared with Taxotere (43% vs 27%), whereas 30% of the men had no preference. The most common factors influencing preferences were fatigue, pain, hair loss, and patient-defined life quality.

,

Adding A Platinum Drug to Chemotherapy

,
Adding A Platinum Drug to Chemotherapy

The study concluded that adding Carboplatin to cabazitaxel showed improved clinical efficacy compared with cabazitaxel alone for men with metastatic castration-resistant prostate cancer. Although adverse events were more common with the combination, the treatment was safe and generally well-tolerated.

,

What Treatment After Zytiga or Xtandi and Chemotherapy Fail?

,

When Xtandi or Zytiga fail what is the best next treatment? We are beginning to better understand how to sequence our advanced prostate cancer treatments, based on the CARD TRIAL using Jevtana after the failure of Zytiga Xtandi and Taxotere might be the superior route.

Gold Guidestar Seal
Gold Transparency 2022